Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ONCY
stocks logo

ONCY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.086
-14%
--
--
-0.073
-8.13%
--
--
-0.074
+6.43%
Estimates Revision
The market is revising No Change the revenue expectations for Oncolytics Biotech Inc. (ONCY) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.48%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-7.48%
In Past 3 Month
Wall Street analysts forecast ONCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ONCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.981
sliders
Low
3.00
Averages
5.50
High
10.00
Current: 0.981
sliders
Low
3.00
Averages
5.50
High
10.00
H.C. Wainwright
H.C. Wainwright
upgrade
$5 -> $10
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$5 -> $10
2025-11-17
upgrade
Reason
H.C. Wainwright raised the firm's price target on Oncolytics to $10 from $5 and keeps a Buy rating on the shares. The firm says the company's "compelling" data in gastrointestinal tumors increase its confidence ahead of the FDA meeting. H.C. Wainwright is increasingly confident that pelareorep is advancing toward "actionable regulatory pathways" across three "high-value" cancer indications.
Lake Street
Chad Messer
initiated
$7
2025-08-13
Reason
Lake Street
Chad Messer
Price Target
$7
2025-08-13
initiated
Reason
Lake Street analyst Chad Messer initiated coverage of Oncolytics with a Buy rating and $7 price target. Oncolytics is emerging under new management with a clear pivotal strategy focused in frontline metastatic pancreatic ductal adenocarcinoma, where "existing clinical data is strong and the unmet need is clear," the analyst tells investors. Pelareorep has shown "impressive" increases in survival compared to both historical results and in a randomized study when added to standard of care regimens, added the analyst, who also notes that the FDA has granted fast track designation to pelareorep in pancreatic cancer.
JonesResearch
Soumit Roy
Buy
to
Hold
downgrade
2025-05-16
Reason
JonesResearch
Soumit Roy
Price Target
2025-05-16
downgrade
Buy
to
Hold
Reason
RBC Capital
Douglas Miehm
Buy
Maintains
$6 → $5
2025-03-10
Reason
RBC Capital
Douglas Miehm
Price Target
$6 → $5
2025-03-10
Maintains
Buy
Reason
RBC Capital lowered the firm's price target on Oncolytics to C$5 from C$6 and keeps an Outperform rating on the shares.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$5
2025-03-10
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$5
2025-03-10
Reiterates
Strong Buy
Reason
Maxim Group
Jason McCarthy
Strong Buy
Maintains
$5 → $3
2025-03-10
Reason
Maxim Group
Jason McCarthy
Price Target
$5 → $3
2025-03-10
Maintains
Strong Buy
Reason
Maxim lowered the firm's price target on Oncolytics to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect the expected dilution from the company needing to raise capital in the near-term to fund its cancer programs, the analyst tells investors in a research note. Maxim adds however that it remains positive on the opportunities for Oncolytics in pela in breast and pancreatic cancer.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Oncolytics Biotech Inc (ONCY.O) is -4.10, compared to its 5-year average forward P/E of -4.72. For a more detailed relative valuation and DCF analysis to assess Oncolytics Biotech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.72
Current PE
-4.10
Overvalued PE
-2.85
Undervalued PE
-6.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.72
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.20
Undervalued EV/EBITDA
-4.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
21.67
Current PS
0.00
Overvalued PS
62.63
Undervalued PS
-19.28
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ONCY News & Events

Events Timeline

(ET)
2025-10-28
07:34:06
Oncolytics announces new findings from pelareorep and atezolizumab study.
select
2025-09-16 (ET)
2025-09-16
07:04:10
Oncolytics shares progress on pelareorep study for gastrointestinal cancers
select
2025-09-08 (ET)
2025-09-08
07:04:41
Oncolytics Reveals Findings from Three mCRC Research Studies
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
12-04Newsfilter
PinnedOncolytics Biotech Initiates FDA Phase 3 Trial, Market Undervalues Potential
  • Market Undervaluation: Oncolytics Biotech's pelareorep is mispriced as a failed immunotherapy, yet it serves as an activator for FDA Phase 3 trials in pancreatic cancer, demonstrating a 62% objective response rate that significantly enhances the company's competitive edge in cancer treatment.
  • Clinical Trial Launch: The FDA has approved a three-arm Phase 3 trial design combining chemotherapy and checkpoint inhibitors, which is expected to drive upward valuation adjustments, especially in a market lacking approved immunotherapy options.
  • Survival Rate Improvement: The two-year survival rate for pancreatic cancer patients using pelareorep reached 21.9%, far exceeding the historical standard of 9.2%, indicating a severe undervaluation of its potential in the market.
  • Management Team Strength: CEO Jared Kelly and CBO Andrew Aromando previously facilitated Ambrx's $2 billion sale to Johnson & Johnson, showcasing the management's execution capability and industry influence, likely attracting more investor attention in the future.
[object Object]
Preview
9.0
12-04Globenewswire
PinnedOncolytics Biotech Initiates FDA Phase 3 Trial for Pelareorep in Pancreatic Cancer
  • Market Mispricing: Oncolytics Biotech's stock is undervalued as the market perceives it as a failed immunotherapy, while in reality, pelareorep acts as an activator for Big Pharma's checkpoint inhibitors, indicating significant market potential.
  • Clinical Trial Initiation: The company has secured FDA alignment to initiate a three-arm Phase 3 trial for first-line pancreatic cancer, which is expected to significantly enhance pelareorep's market recognition and drive a valuation rebound.
  • Survival Rate Improvement: In pancreatic cancer patients, the combination of pelareorep with chemotherapy achieved a 62% objective response rate and a two-year survival rate of 21.9%, far exceeding the historical standard of 9.2%, highlighting its therapeutic importance.
  • Management Team Strength: CEO Jared Kelly and CBO Andrew Aromando previously engineered Ambrx's $2 billion sale to J&J, providing strong leadership support for Oncolytics' future growth.
[object Object]
Preview
4.0
11-20NASDAQ.COM
Everything You Should Know About the Upgrade to Buy for Oncolytics Biotech (ONCY)

  • Zacks Rank Upgrade: Oncolytics Biotech Inc. (ONCY) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which are crucial for stock price movements.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for Oncolytics has increased by 13.1% over the past three months, reflecting a favorable change in the company's earnings potential.

  • Investment Strategy: The Zacks rating system, which balances buy and sell ratings, positions ONCY in the top 20% of stocks based on earnings estimate revisions, suggesting it may outperform the market.

  • Market Trends: The article highlights the growing demand for data and the potential for under-the-radar chipmakers to benefit from the next phase of market growth, similar to companies like NVIDIA.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Oncolytics Biotech Inc (ONCY) stock price today?

The current price of ONCY is 0.9807 USD — it has increased 8.16 % in the last trading day.

arrow icon

What is Oncolytics Biotech Inc (ONCY)'s business?

Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

arrow icon

What is the price predicton of ONCY Stock?

Wall Street analysts forecast ONCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONCY is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Oncolytics Biotech Inc (ONCY)'s revenue for the last quarter?

Oncolytics Biotech Inc revenue for the last quarter amounts to -13.84M USD, increased 39.81 % YoY.

arrow icon

What is Oncolytics Biotech Inc (ONCY)'s earnings per share (EPS) for the last quarter?

Oncolytics Biotech Inc. EPS for the last quarter amounts to -6658000.00 USD, increased 36.88 % YoY.

arrow icon

What changes have occurred in the market's expectations for Oncolytics Biotech Inc (ONCY)'s fundamentals?

The market is revising No Change the revenue expectations for Oncolytics Biotech Inc. (ONCY) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.48%.
arrow icon

How many employees does Oncolytics Biotech Inc (ONCY). have?

Oncolytics Biotech Inc (ONCY) has 27 emplpoyees as of December 05 2025.

arrow icon

What is Oncolytics Biotech Inc (ONCY) market cap?

Today ONCY has the market capitalization of 104.10M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free